SWEDISH ORPHAN BIOVIT ORD by Swedish Orphan Biovitrum AB (BIOVF) Stock Price, Quote, News & History

Key Statistics

Open

Volume / Avg.

10.00 / 563.00

Day Range

- - -

52 Wk Range

33.30 - 49.03

Market Cap

P/E Ratio

121.01

Dividend Yield

Exchange

OTC

RSI

Short Interest

Days to Cover

999.99

Recent Swedish Orphan Biovitrum AB (publ) News

Merck Virus Treatment Shows 60.4% Effectiveness, Reduces Certain Infections In Infants

Merck announces positive results from Phase 2b/3 and interim Phase 3 trials of a monoclonal antibody designed to protect infants from RSV.

Vandana Singh

Apellis Pharmaceuticals' Pegcetacoplan Meets Primary Goal In Late-Stage Study In Patients With Rare Kidney Diseases

Swedish Orphan Biovitrum and Apellis Pharmaceuticals released topline results from the Phase 3 VALIANT study of pegcetacoplan for C3 glomerulopathy and IC-MPGN. The study met primary and secondary endpoints, showing proteinuria and kidney inflammation reductions.

Vandana Singh

Pfizer, Sanofi's Respiratory Syncytial Virus Products Faces Insurance And Logistical Hurdles To Protect Infants

As the respiratory virus season kicks off, healthcare providers are racing against time to offer Pfizer Inc's (NYSE: PFE) vaccine, Abrysvo, to pregnant patients and Sanofi SA's (NASDAQ:

Vandana Singh

Unanimous Support for AstraZeneca and Sanofi's Nirsevimab: Next Generation RSV Treatment on the Horizon

The FDA's Antimicrobial Drugs Advisory Committee has voted unanimously 21 to 0 that AstraZeneca plc (NASDAQ: AZN) and Sanofi SA's (NASDAQ: SNY) nirsevimab has a favorable benefit-risk profile t

Vandana Singh

Apellis Pharma Flunks On Primary, Secondary Endpoints In Amyotrophic Lateral Sclerosis Study

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

7.86B

Investing Cash Flow (TTM)

-12.90B

Financing Cash Flow (TTM)

5.04B

Free Cash Flow (TTM)

4.55B

Capital Expenditure (TTM)

-3.32B

Net Change in Cash (TTM)

2.00M

Valuation Metrics

Enterprise Value

$17.48B

PE Ratio (TTM)

121.01

PE Ratio (FWD)

21.14

PEG Ratio (TTM)

0.28

PS Ratio (TTM)

5.41

PB Ratio (TTM)

3.90

Earnings Yield % (TTM)

0.83%

Earnings Yield % (FWD)

4.73%

EV / EBITDA (TTM)

13.59

Price / EBITDA (TTM)

13.11

Price / Free Cash Flow (TTM)

36.43

Book Value / Share

$12.35

Company Debt

Total Debt

$17.21B

LT Debt

$8.48B

LT Debt Issuance (TTM)

LT Debt Repayment (TTM)

Total Cash

$1.08B

Debt to Equity

0.42

Issuance of Debt (TTM)

$4.58B

Repayment of Debt (TTM)

Key Statistics

Open

Volume / Avg.

10.00 / 563.00

Day Range

- - -

52 Wk Range

33.30 - 49.03

Market Cap

P/E Ratio

121.01

Dividend Yield

Exchange

OTC

RSI

Short Interest

Days to Cover

999.99

About

Sector

Health Care

Industry

Biotechnology

Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) in 20...

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS better than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

BIOVF

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS better than industry

BIOVF

FAQ

How do I buy SWEDISH ORPHAN BIOVIT ORD by Swedish Orphan Biovitrum AB (BIOVF) stock?

You can purchase shares of SWEDISH ORPHAN BIOVIT ORD by Swedish Orphan Biovitrum AB (OTCPK:BIOVF) through any online brokerage.

View our list of the best stock brokerages

Who are SWEDISH ORPHAN BIOVIT ORD by Swedish Orphan Biovitrum AB (BIOVF) competitors?

There are no as such competitors for SWEDISH ORPHAN BIOVIT ORD by Swedish Orphan Biovitrum AB.

What is the forecast, or price target, for SWEDISH ORPHAN BIOVIT ORD by Swedish Orphan Biovitrum AB (BIOVF) stock?

There is no analysis for SWEDISH ORPHAN BIOVIT ORD by Swedish Orphan Biovitrum AB to provide a consensus price target.

What is the current price for SWEDISH ORPHAN BIOVIT ORD by Swedish Orphan Biovitrum AB (BIOVF)?

The stock price for SWEDISH ORPHAN BIOVIT ORD by Swedish Orphan Biovitrum AB (OTCPK: BIOVF) is $48.1264 last updated September 3, 2026 at 3:11 PM EDT.

Does SWEDISH ORPHAN BIOVIT ORD by Swedish Orphan Biovitrum AB (BIOVF) pay a dividend?

There are no upcoming dividends for SWEDISH ORPHAN BIOVIT ORD by Swedish Orphan Biovitrum AB.

When is SWEDISH ORPHAN BIOVIT ORD by Swedish Orphan Biovitrum AB (OTCPK:BIOVF) reporting earnings?

SWEDISH ORPHAN BIOVIT ORD by Swedish Orphan Biovitrum AB does not have any upcoming earnings scheduled.

Is SWEDISH ORPHAN BIOVIT ORD by Swedish Orphan Biovitrum AB (BIOVF) going to split?

There is no upcoming split for SWEDISH ORPHAN BIOVIT ORD by Swedish Orphan Biovitrum AB.

What sector and industry does SWEDISH ORPHAN BIOVIT ORD by Swedish Orphan Biovitrum AB (BIOVF) operate in?

SWEDISH ORPHAN BIOVIT ORD by Swedish Orphan Biovitrum AB is in the Health Care sector and Biotechnology industry. They are listed on the OTCPK.